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Abstract
The upsurge of resistance in classes of antibiotics in varied bacterial species has increased 
the search for alternatives to antibiotics in bacterial infections. However, one alterna-
tive is the beneficial bacteria in foods, environment and gut. Probiotics is now being 
embraced as an alternative strategy to combat antibiotic resistant pathogens. A newer 
application is gut microbiota in its healthy state combating pathogenic and antibiotic 
resistant microbes. There have been numerous applications of beneficial bacteria against 
different infectious agents. This article describes the concept of beneficial microbes as 
antimicrobial agents with current applications as antimicrobial agents, various applica-
tions in the human gut with future directions.
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1. Introduction
Microorganisms exist from where we can imagine to places we least expect e.g. outer space 
and the dead sea. Much of the global atmospheric oxygen is as a result of microbial activity 
[1]. They also maintain the gut health by regulating the microflora, stimulating the develop-
ment of the immune system, production and enhancement of some important nutrients [2] 
and there seem to be a natural interdependence of life on microorganisms.
At the time of antibiotic discovery, Fleming looked into the future and foresaw that antimi-
crobial resistance would be a challenge, and he gave a subtle warning about the potential 
impact of sub-optimal dosage in fostering antimicrobial resistance during his Nobel laureate 
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acceptance speech. Unfortunately, about 10 years after Penicillin was discovered, Fleming’s 
fears were confirmed when penicillin-resistant pathogens emerged. Since then (and for more 
than half of a century later), the discovery of a novel antibiotic has always been accompanied 
by the eventual emergence of antibiotic-resistant strains due to regular and inappropriate 
usage of antibiotics by humans [3]. Antimicrobial drug resistance is a global threat to pub-
lic health and human activities contribute significantly to the selection of resistant strains 
through non prudent use of these antimicrobial agents giving rise to the development of a 
generation of antimicrobial resistant mutants circulating in the biosphere [3]. Unfortunately, 
resistance has eventually been seen to nearly all antibiotics that have been developed [4].
2. Probiotics
“Probiotics are live microorganisms which when administered in adequate amount confer 
a health benefit on the host” [5]. The concept of probiotics evolved from the work of Elie 
Metchnikoff in the early twentieth century when he observed that certain beneficial microbes 
particularly lactic acid bacteria in milk consumed by peasant Bulgarians were responsible for 
their longevity. Lactic acid bacteria and Bifidobacteria are the most commonly used organ-
isms as probiotics, although some other bacteria such as Escherichia coli Nissle 1917 [6] and 
yeast such as Saccharomyces boulardii are also used [7]. Lactobacillus spp. being an integral part 
of the intestinal microflora having earned the “Generally Regarded as Safe“ status are the 
most successful probiotic candidates. Lactic acid producing bacteria are known to possess 
various health benefits such as anti-cancer activity, lowering of serum cholesterol, lactose 
intolerance alleviation, prevention of antibiotic related diarrhea, stimulation of the immune 
functions, antimicrobial activity against resistant pathogens [8, 9] prevention and treatment of 
Inflammatory bowel disease [10], respiratory viral infection [11]. Recently, Lactobacillus spp. 
have also been reported to have beneficial effects in patients suffering psychological disor-
ders, such as depression and anxiety [12–14]. Probiotics have been proposed to exert health 
benefits through several mechanisms [15], these include enhancement of the epithelial barrier, 
increased adhesion to intestinal mucosa, and concomitant inhibition of pathogen adhesion, 
competitive exclusion of pathogenic microorganisms, production of antimicrobial substances 
and modulation of the immune system. For example, E. coli Nissle 1917 has been used as an 
alternative treatment option of Ulcerative colitis—a chronic intestinal disease [16]. Generally, 
LAB and probiotics augment the antagonistic activity of the gut commensals against infec-
tious agents, including the opportunistic pathogen Clostridium difficile that is implicated in 
antibiotic-associated diarrhea [17]. Other probiotics have been confirmed to prevent intestinal 
infections (such as stomach infections caused by Helicobacter pylori) and extra-intestinal infec-
tions (such as infections of the respiratory tract). This way, the spread of antibiotic resistance 
diminishes drastically, and the gut microbiota structure and overall health of the host is 
restored. This bodes well for the future of the human race. The probiotic properties are strain 
specific and cannot be extrapolated to other strains of the same species, also the organisms are 
to be administered live hence, they must be safe and produce the desired beneficial effect [18].
There are critical guidelines on the minimum requirement for the selection of probiotic strains 
as recommended by Food and Agricultural Organization of the World Health Organization 
[5] and can be summarized as;
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2.1. Identification of genus, species and strain
Since the probiotic property is a strain specific attribute, it will be important to link specific 
health benefit to a particular strain and also for epidemiological surveillance purposes, the 
proposed microorganism must be identified to the strain level, the strains should be correctly 
identified using both phenotypic and genotypic methods and deposited in an internationally 
recognized culture collection [19], molecular methods such as DNA/DNA hybridization and 
16S rRNA gene sequencing are suggested for strain identification.
2.2. Assessment of safety
Selected strain must be non-pathogenic, non-haemolytic and non-toxic in the intended host. 
They must be safe and qualify for the qualified presumption of safety (QPS) as stipulated 
by European Food Safety Authority. The antibiotic resistance susceptibility pattern includ-
ing the MIC to antibiotics of medical importance should be determined, the intended strain 
should not possess antimicrobial resistance determinants [18]. Probiotic strains should also be 
assessed for metabolic activities such as production of D-lactate and bile salt deconjugation. 
Assessment of toxin production should be done for microbial strains that belong to species 
that are known to produce mammalian toxins. The demonstration of lack of infectivity of 
the probiotic strain in animals with deficient immune functions will further substantiate the 
safety profile of such strain. A post market epidemiological surveillance of adverse effects in 
the host is also an important safety requirement.
2.3. Functional considerations
2.3.1. Resistance to bile salt and gastric conditions
Probiotic strains intended for oral administration must be able to survive passage through the 
gastrointestinal tract of the host, where they will encounter an hostile condition characterized 
with low pH and bile salt and must survive in adequate amount to confer health benefit on the 
host. Lactic acid bacteria isolated from the guts tends to better survive this route than those 
isolated from other sources [9].
2.3.2. Ability to adhere and colonize the epithelial cells and tissues
The ability of the probiotic strain to adhere to intestinal mucosa and epithelial cells is an 
important characteristic for its colonization and survival in the host. Successful coloniza-
tion of the intestinal mucosa by probiotics is important for immune modulation and inhibi-
tion of pathogens by competitive exclusion. Microorganisms that have poor adherence to 
epithelial cells will easily be washed away and unlikely to colonize the host for a probiotic 
effect [9].
2.3.3. In vivo validation of health benefits
Probiotics must be able to exert health benefits through their activities in the host, in vitro 
tests to predict the health benefits to host may not be sufficient. In vivo experiments should be 
carried out to validate in vitro health benefit potentials.
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2.4. Overview of approved probiotic strains currently used
Health agencies in different countries have specific microorganisms approved as probiot-
ics. For example, Health Canada approves the use of Lactobacillus johnsonii La1, Lj1, or NCC 
533 strains (to treat Helicobacter pylori infections), Lactobacillus rhamnosus GG (for prevention/
management of antibiotic-associated diarrhea), and Saccharomyces boulardii/S. cerevisiae (for 
prevention/management of antibiotic-associated diarrhea) in doses of ≥107 colony forming 
units (CFU) daily [20]. Other probiotics strains has also been approved by Health Canada [20]. 
US FDA also have a comprehensive list of approved probiotic metabolites for use as food 
ingredients or additives after they have been certified as GRAS e.g. Streptomyces natalensis and 
Streptomyces chattanoogensis in Natamycin [21]. A probiotic strain is usually identified with 
internationally approved methods; by the genus, species, subspecies (where applicable), and 
the specific strain designated with an alphanumeric identity e.g. Lactobacillus casei DN-114. 
Probiotic strain designation is vital, since health benefit(s) to the host must be linked to the 
particular strain or a combination of strains and these benefits are strain specific. The WHO/
FAO guideline stipulates that probiotic strains should be registered in an internationally rec-
ognized culture collection [5].
Lactobacillus and Bifidobacteria species are the most commonly used probiotic microorgan-
isms, however, some strains of Escherichia coli, Bacillus species and the yeast Saccharomyces 
boulardii are also used. Recently, Clostridium butyricum was also approved for probiotic use in 
European Union [22].
2.5. Challenges encountered in formulation and use of probiotics
Due to the well-known benefits of probiotics, food companies incorporate probiotics into 
foods (termed functional foods) for greater marketability [23]. However, there is always a ten-
dency for these probiotic strains to be lost or greatly reduced in number and viability during 
food processing and/or storage such that the purported health benefit is eventually lost. Thus, 
probiotic instability is one challenge faced by food formulators and manufacturers that intend 
to incorporate probiotic strains into their product. The shelf life is mostly unpredictable, so 
much that excess of up to 200% viable cells are added in probiotic products to make-up for 
cells that die before it reaches the consumer, this makes backing up label claims difficult and 
also increases the production cost. Manufacturers also have to prove that the probiotics will 
still remain stable and viable within the human body in adequate amounts until they reach 
the gut where their impact is the greatest [23].
2.6. Antimicrobial activities against pathogens
The ability of the proposed probiotic strain to produce antimicrobial substances against 
pathogens is an important consideration in the selection of probiotic strains. Lactic acid bacte-
ria produce antimicrobial metabolic compounds during lactic fermentation such as hydrogen 
peroxides, organic acids such as lactic, acetic and propionic acid. Bacteriocins and other pro-
teinaceous inhibitory substances are also produced by some probiotic organisms [24].
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2.6.1. Organic acids
The end product of fermentation of lactic acid bacteria include organic acids such as lac-
tic acid, acetic acid, propionic acid, butyric acid etc. which reduces the pH of their growth 
medium and thus makes it unfavorable for the growth of other competing microorganisms. 
The organic acids exert their antimicrobial activity by interfering with the integrity of the 
cell membrane, inhibition of various metabolic functions and active transport, lowering of 
intracellular pH [25].
2.6.2. Hydrogen peroxide
Lactic acid bacteria do not utilize the cytochrome system as a result of lack of the heme group 
and thus cannot reduce oxygen to water leading to the production of hydrogen peroxide from 
the action of flavoprotein oxidases or NAD peroxides. The hydrogen peroxide is produced in 
amount capable of bacterial antagonism particularly against species which lack catalase per-
oxidase. Free radicals such as hydroxyl radical and superoxides which can damage bacteria 
DNA may also have hydrogen peroxide as precursor for their production. Lactic acid bacteria 
had been reported to produce hydrogen peroxide as part of its inhibitory mechanisms [9].
2.6.3. Bacteriocin
Some lactic acid bacteria produce small, heat-stable, ribosomally synthesized inhibitory 
bioactive peptides produced during their primary phase of growth called bacteriocin. Many 
bacteriocins exhibit a narrow spectrum of antimicrobial activity, particularly against bacteria 
strains of species related to the bacteriocin producing species while some display activity 
across a variety of different bacteria genera. Bacteriocins exhibit a wide diversity as regards 
their structure, size, mechanism of action, inhibitory spectrum and target cell receptors [26]. 
Most of the bacteriocins produced by LAB appears to have a narrow spectrum of antimicrobial 
activity, however nisin and pediocin are known to exhibit a broad antibacterial spectrum [23]. 
Bacteriocins are easily degraded by proteolytic enzymes particularly by those produced by 
the guts of mammals which make them safe for human use [27]. Generally, bacteriocins can 
be sub-divided into three classes according to their structure and mode of antibacterial action. 
Class I bacteriocins include nisin, which is active against Gram positive bacteria including food 
spoilage and pathogenic microbes. Nisin has a pentacyclic structure composed of 34 amino 
acids with one lanthionine residue (Ring A) and four beta-methyllanthionine residues (rings 
B, C, D, E), heat stable at 121°C but becomes less heat stable on prolong heating, especially 
between pH 5 and 7 [27]. Bacteriocin has proven to be an efficient natural antimicrobial agent 
against pathogens and food spoilage bacteria, including Listeria monocytogenes, Staphylococcus 
aureus, Bacillus cereus and Clostridium botulinum [28].
Enterocin X, plantaricin A and lactococcin G are class 2b bacteriocins commonly produced by 
Enterococcus faecium and lysostaphin, enterolysin A, helveticin J are common class 3 bacterio-
cins produced by Lactobacillus helveticus, they are heat stable with a large molecular weight 
of more than 30 kDa [29]. Nisin is the only bacteriocin that has been officially approved for 
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use in the food industry [30], class II bacteriocins are relatively small, heat-stable and contain 
peptides while Class III bacteriocins are heat stable and also have a relatively large molecular 
weight [27]. The classes of bacteriocins produced by Gram-positive beneficial bacteria include 
lantibiotics and non-lantibiotic heat stable proteins [31] while Gram-negative bacteria pro-
duce colicin and microcin [32].
2.6.4. Prebiotics
Prebiotics are non-digestible food products that increase the relative abundance of beneficial 
microorganisms in the gut when ingested. Similar to the influence of complex plant polysac-
charides on the gut microbiota composition and beneficial metabolite production, prebiotics 
enhance the production of short chain fatty acids such as butyrate—a metabolite that serves 
as an energy source for colonic epithelium. Examples of prebiotics used include inulin, fruc-
tooligosaccharides, and galactooligosaccharides, Some of these prebiotics are found naturally 
in foods (such as barley, wheat), and in garlic and raw onions. These prebiotics have been 
applied in malnourished Thai children and children from certain countries in Africa [33], 
South America and Europe in order to improve the adsorption of calcium as well as improve-
ment of growth [34].
3. Synbiotics
Synbiotics is a term used for the combined use of probiotics and prebiotics to achieve a more 
efficient impact on the gut microbiota [34]. This concept surfaced in order to tackle possible 
difficulty of the probiotics to establish itself in the gut. In this case, prebiotics and probiotics 
are co-administered in order to improve the growth/relative abundance and establishment 
of probiotics in the gastrointestinal tract of its host. The probiotic strains used in conjunction 
with prebiotics include Lactobacilli and Bifidobacilli, while the prebiotics used along with 
probiotic strains include inulin, galactooligosaccharide, and fructooligosaccharide. The com-
bination of probiotics and prebiotics in therapy helps to give stability to the gut microbiota, 
which translates to overall health of the host’s gut and the host in general. This combination 
also helps to enhance antimicrobial activity, and the combined effect includes; competition 
with the pathogen for adherence sites, production of metabolites that are toxic to the patho-
gens, production of compounds that degrade toxins produced by the pathogens, obstruction 
of attachment sites and toxin receptors, and modulation of the immune system to respond 
effectively to pathogen invasion [35].
4. Antimicrobial potentials of beneficial microbes against antibiotic 
resistant strains
The antimicrobial activities of beneficial microorganisms particularly lactic acid bacteria iso-
lated from various sources against pathogens have been reported by many authors [7, 36]. 
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Afolayan et al. [37] isolated lactic acid bacteria from different variety of “Ogi” a fermented 
cereal in western part of Nigeria with antimicrobial activities against various gastrointestinal 
pathogens. Shigella spp. are enteric pathogens which cause dysentery and diarrhea and are a 
leading cause of gastroenteritis- associated deaths in about 3–5 million under 5 years old chil-
dren in developing countries [38, 39]. Lactic acid bacteria strongly inhibited gastrointestinal 
E. coli in co culture [40]. Cell free supernatant of Lactobacillus casei isolated from traditional 
yoghurt and milk was reported to strongly inhibit multi-drug resistant Shigella sonnei and 
S. flexneri [39], and also starter cultures in Nigerian yoghurt and the yoghurt itself has been 
reported to have strong inhibitory effects on gastrointestinal pathogens [41]. Salmonellosis 
contributes significantly to global morbidity and mortality. There are about 93.4 million cases 
of salmonellosis worldwide resulting in 155,000 death annually [42], Lactobacillus spp. with 
antimicrobial activity against Salmonella typhi were isolated by Abdel-Daim et al. [43] and in 
vivo anti-salmonella activities of lactobacilli has also been reported by Casey et al. [44] in pigs. 
Antimicrobial activities of lactic acid bacteria has also been reported against Pseudomonas 
aeruginosa, Providencia vermicola, Alcaligenes faecalis and MRSA in co culture [45].
The increasing emergence of antibiotic resistant uropathogens, yeast infection and recurrent 
infection has necessitated special interest in the antibacterial activity of lactic acid bacteria 
against uropathogens [46]. There are increasing scientific evidences that LAB can prevent 
the growth and attachment of pathogens to epithelial cells [47]. It was reported by Adeniyi 
et al. [48] that lactic acid bacteria isolated from various Nigerian based fermented foods 
exhibited varying antimicrobial activity against organisms implicated in urinary tract infec-
tions. Weissella spp. isolated from African fermented food and cow intestine demonstrated 
significant inhibitory activity against multi drug resistant uropathogens [7]. Lactic acid 
bacteria isolated from a menstruating Nigerian woman was shown to have antimicrobial 
activity against an array of uropathogens; Escherichia coli, Proteus mirabilis 42P, Pseudomonas 
aeruginosa, Citrobacter freundii and Enterobacter cloacae [49]. The organic acid produced by lactic 
acid bacteria has been proven to be inhibitory to Neisseria gonorrhoeae [50]. The antibacterial 
activity of lactic acid bacteria isolated from selected Nigerian vegetables against Pseudomonas 
aeruginosa, Escherichia coli, Proteus penneri, and Enterococcus faecalis was published by Bamidele 
et al. [51]. Lactobacillus spp. have been reported to inhibit the growth of Candida albicans and 
prevent the relapse of yeast infection [52]. The metabolite of Lactobacillus plantarum strain N4 
was discovered to possess antiviral activities against coronavirus causing gastroenteritis [53], 
certain lactic acid bacteria have been suggested to be effective in reducing the severity and 
duration of acute rotavirus gastroenteritis [54].
5. Beneficial microbes in the gut; effects on antibiotic resistant 
strains
In the gut lies a community of beneficial microorganisms that have carved a niche and have 
evolved with humans over several generations—collectively known as the gut microbiota. 
Microorganisms that make up the gut microbiota include members of bacteria, fungi, viruses, 
archaea, and protists. Before the advent of next-generation sequencing technologies, very 
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little was known about the composition and functions of this microbial community, and as 
such were not thought as agents to be considered in health and disease. Now, we are just 
beginning to scratch the surface of the potentials of this novel ‘organ’, and its implication in 
the overall health of humans. It is referred to as an ‘organ’ because the gut microbiome (the 
gut microbiota, gut microbial genomes, and the living environment) is made of millions of 
bacterial cells that collectively weigh about 1.5 kg, possesses about 150 times more genes 
than human genes, and contribute significantly to human health. As a result of advances in 
research, scientists are beginning to appreciate the beneficial roles of gut microbes, and their 
symbiotic relationship with us, their host. Although previously thought to be responsible for 
the production of essential vitamins B and K alone, the gut microbiota has been discovered to 
be implicated in various aspect of human health, and its effects extend beyond the gastroin-
testinal tract through the release of biosynthesized metabolites (by the gut microbes) from the 
gut into the systemic circulation. For example, the response of immune cells to inflammation 
is modulated by the gut microbiota [55]. The effect of these metabolites extends even to the 
central nervous system where they influence behavior, mood, and emotions.
In the gastrointestinal tract, the gut microbiota protects the gut against invading pathogens 
by competing with them for nutrients and attachment site. Most of the antibiotic-resistant 
disease-causing infectious agents that invade the gastrointestinal tract are food-borne or 
water-borne, and they include Salmonella, Shigella, Campylobacter, and Listeria monocyto-
genes. On the other hand, the gut microbiota is dominated by members of the Firmicutes, 
Bacteroidetes, Proteobacteria, and Actinobacteria. Other less dominant bacterial phyla 
include the Fusobacteria, Tenericutes, Spirochaetes (differentially abundant in the gut of 
hunter-gatherers and rural individuals who consume plant-based foods), Elusimicrobia, and 
Verrucomicrobia. Prevotella—a member of the phylum Bacteroidetes—has also been found to 
be more abundant in individuals whose lifestyle resembles those of the Paleolithic (such as 
the hunter-gatherers) and Neolithic (such as the subsistence agriculturalists) era. Conversely, 
Bacteroides—another member of Bacteroidetes—is more abundant in populations that practice 
a westernized lifestyle, characterized by high-fat, low-fiber diet. Many of the gut commen-
sals such as Eubacterium, Ruminococcus, Roseburia, and Faecalibacterium are members of the 
Firmicutes that produce short-chain fatty acids (such as butyrate, acetate, and propionate) 
as a product of microbial fermentation (the breakdown of complex polysaccharides), and 
these acids diminish diarrhea and gastrointestinal inflammation. These short chain fatty 
acids (SCFA) also create a harsh environment for the colonization of invading gastrointestinal 
pathogens by the reduction of intestinal pH. Other pathogen-inhibiting metabolites produced 
by gut commensals include phenols, ammonia, bacteriocins, and ammonia [56].
The composition of the gut microbiota can be positively or negatively affected by dietary habits 
and other lifestyle factors, the use of antibiotics, age, the state of health, and surgery amongst 
other factors [57]. The regular consumption of a fiber-rich, plant-based diet improves the com-
positional profile of the gut microbiota in terms of richness and diversity, and also improves the 
functional capabilities of the members of the gut microbiota. Good lifestyle practices such as 
the consumption of fiber-rich foods and fruits increases the relative abundance of beneficial gut 
microbes which produce metabolites that are responsible for overall gut epithelial health [58]. 
The impact of diet on the stability of the gut microbiota cannot be overemphasized. This is 
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because an imbalance in the structure of the gut microbiota is a risky phenomenon in the 
development of gastrointestinal and extra-gastrointestinal diseases. Antibiotics do not differ-
entiate between beneficial bacteria and pathogenic bacteria, and as such, there is a significant 
decrease in the richness and diversity of the gut microbiota after antibiotic administration. 
This places a fatal dent on gut microbiota stability and creates an environment for opportunis-
tic pathogens such as antibiotic-associated Clostridium difficile to thrive resulting in diarrhea. 
Dysbiosis (impairment in the natural balance) of the gut microbiota has been associated not 
only with the risk of antibiotic-associated diarrhea, but a plethora of other diseases such as 
type 2 diabetes, cancer, obesity, inflammatory bowel diseases and irritable bowel syndrome 
[59]. Adulthood is generally characterized by a stable gut microbiota, with occasional shifts 
in gut microbial diversity due to change in dietary habits, medication, illness or travel. On the 
other hand, the gut microbiota of infants is quite volatile and changes rapidly depending on 
the mode of birth, whether they are breast-fed or formula-fed, and whether they have been 
weaned or not. By the age of 2–5 years, their gut microbiota begins to resemble that of a typi-
cal adult. At the tail end of life, age-related changes in physiology of the body and changes 
in dietary habits due to loss of dentition could have a negative impact on the gut microbiota 
thereby making it less stable [60]. At this age also, the use of medication is high because they 
are more prone to diseases and impairments, which could influence gut microbial profiles. All 
of these factors mentioned above have to be considered when designing strategies aimed at 
restoring or contributing to the natural balance of the gut microbiota.
6. Current applications
The beneficial role played by bacteria in ingested fermented foods was linked to increased 
longevity in Balkans [61]. The administration of probiotics has also reduced the shedding of a 
pathogenic serotype of E. coli (E. coli O157: H7) by farm animals, thereby reducing the spread 
of these resistant strains from animals to humans who handle them regularly [62]. Also, there 
is hope that probiotics wills soon replace antibiotics in the veterinary field to treat diseases of 
farm animals while enhancing the growth of these farm animals. This way, antibiotic-resistant 
zoonotic pathogens do not re-emerge and enter the food chain. Also, the cost of production 
and maintenance of livestock will drop significantly if probiotics are being utilized rather 
than antibiotics.
Researchers and clinicians are getting conscious of the fact that probiotics isolated from the 
host have a higher tendency to remain endogenous when administered than probiotics gotten 
from other sources. This fact informs their decision on the choice of probiotics to be adminis-
tered. Capsules of probiotics are sometimes used in concert with antibiotics to treat particular 
diseases with greater effect than if either of them (probiotics or antibiotics) was used alone 
[17]. This co-administration is done with the hope that this action will reduce antibiotic selec-
tive pressure, and decrease the emergence of drug-resistant pathogens. Currently, research 
is ongoing on the packaging of lyophilized lactic acid bacteria into capsules so that they can 
be used in the veterinary field (as probiotics) to inhibit the proliferation of zoonotic patho-
gens [36]. This method will limit the spread of diseases from animals to humans through 
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animal-derived products. Probiotics have been introduced into milk, formula, and other 
infant foods as a supplement, in order to improve the human gut microbiota stability and tap 
into the purported benefits of probiotics. The viability of probiotics is enhanced in its lyophi-
lized state within low-fat milk or fruit juice by food formulators and manufacturers [22]. The 
improvement of the viability of probiotic strains can also be achieved by microcapsulation—a 
formulation approach that employs the use of microcapsules to package solids, liquids, or 
gases where these contents could be released in a controlled manner under specific condi-
tions [22]. With this technique, the formulation, storage, and successful transport of probiotic 
strains to their destination in the gut is assured. Although probiotics are generally regarded as 
safe, there is a conscious effort to confirm that they do not carry and transfer genes conferring 
antimicrobial resistance, as this will defeat the purpose of probiotics usage [63]. By and large, 
the ultimate aim of the use of probiotics is to ensure the stability of the human and animal 
gut microbiota so as to take advantage of the symbiotic activity of the probiotic and the gut 
microbial community in the fight against multi-drug resistant gastrointestinal pathogens [8].
Probiotics are most commonly sold as foods or food supplements, powders, lozenges, tablets 
(could be chewable, enterocoated or not), sticks, capsules, bottle caps, sachets, stick packs, 
and oil suspensions (usually for babies) probiotic nasal spray and ointments have also been 
developed. Most probiotic products available in the market are dairy based foods, includ-
ing fermented milks, yogurts, cheese etc. The health claims on most probiotics labels tend 
to be general and such products are intended for the general healthy population. However, 
manufacturers, food companies, and the media have dispersed unproven information about 
the purported health benefits of probiotics even before a comprehensive clinical trial has 
been conducted to validate the efficacy, and the risk–benefit association In terms of probiot-
ics acceptability, although probiotics have been used in the food industries for decades, the 
discovery of novel strains and genetic manipulation of known strains (some of which are 
pathogenic) is usually accompanied with a mirror image of the consumer skepticism associ-
ated with the marketing of genetically modified foods.
Another current application of beneficial gut microbes is the method of fecal microbiota 
transplantation (FMT). Fecal microbiota transplantation is a technique that involves the 
reconstitution of the deliberately-emptied gut of gastrointestinal-diseased patients with the 
gut microbiota of healthy donor as a therapeutic alternative measure to antibiotic adminis-
tration for the restoration of the healthy gut microbiota [64]. This method has enabled the 
majority of those who have been suffering from antibiotic-associated diarrhea and inflam-
matory bowel diseases to lead a normal life after treatment. Although the filtered donor stool 
suspension can be passed into the gut of the recipient through rectal enema, nasoduodenal 
tube, or the nasogastric tube, colonoscopy is the most preferred method of stool suspension 
transfer. These donor stools could also be lyophilized and packaged into capsules, to be used 
in treating gastrointestinal infections. Stool banks are currently available in Europe and North 
America for the storage of tested, pathogen-free donor stools until they are needed by the 
medical practitioners [65]. Knowledge about the microbial composition of each donor stool 
and other components of the stool will also inform the medical practitioner and the patient 
on what to expect after transplantation. Due to the fact that the mental receptiveness of the 
fecal microbiota transplantation by the patient could have an effect on the effectiveness of this 
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procedure, and the fact that there is a risk of undetected pathogens/diseases transfer from 
the donor to the recipient, some scientists advocate for an alternative to FMT. They believe 
that isolation and identification of the key players in the restoration of gut microbiota balance 
will help in the design of a consortium of these microbial players. An artificial stool could be 
prepared using this donor-sourced purified consortium of gut bacteria which would then 
replace the use of the donor stools in a less risky, more efficient and more mentally-acceptable 
manner [66]. This burgeoning field is known as Microbial Ecosystem Therapeutics.
7. Future directions
As previously mentioned, MET is one proposed alternative to FMT. Apart from the fact that 
this procedure is less disgusting and less risky than FMT, it has the potential to be regulated 
and standardized more efficiently than FMT [67]. MET procedure involves the isolation, 
characterization, and screening of gut microbes (for antibiotic resistance, presence of viru-
lence determinants, etc.) from a healthy donor. Gut microbes that pass the screening test will 
then be recombined into a microbial ecosystem where their combined efforts and synergistic 
relationships will be more effective in tackling invasive enteropathogens and opportunis-
tic pathogens such as Clostridium difficile [68]. In the future, this consortium of synergistic 
gut microorganisms will be packaged and lyophilized in their live form into capsules and 
prescribed as a drug. MET is still in its infancy, and it also has to go through regulatory 
procedures just like a drug, and standardized before it is globally accepted for use in treat-
ing gastrointestinal diseases such as antibiotic-induced diarrhea as a therapeutic alternative 
measure to antibiotic administration. Nevertheless, it offers a promising and a more effective 
alternative to the use of FMT. Furthermore, since the exact composition of the consortium is 
defined, it will be easy to track the long-term effect of this potential drug on human health. 
Also, questions about the interaction between the consortium and the resident gut microbiota 
and their combined effect on the health of the human host will be answered in detail when 
this emerging procedure is studied in detail (which can be aided by adequate funding and 
government support) [67]. In the future, these studies will also open our eyes to the benefits 
MET has over FMT, and whether there are risks associated with the MET procedure. This 
information will give the medical community a holistic idea about the merits and demerits 
of the MET procedure, and will allow the medical practitioners (and patients) to make an 
informed decision on whether to use MET or stick to FMT or antibiotic administration (or a 
combination of either two of the three options, or combination of the three options). It will 
also be interesting to find out whether the MET procedure will be effective in the treatment of 
extra-intestinal diseases in the nearest future [67].
For the advancement of personalized medicine, another prospect is the use of antimicrobial 
peptides and/or nucleic acid-based methods to selectively kill pathogenic microorganisms in 
the gut without compromising the structure or function of the gut microbiota (a prominent 
demerit of antibiotics usage) [69]. Probiotic strains and the gut microbiota have also been 
thought of as reliable sources of new antimicrobial peptides and antimicrobials, such as bacte-
riocins [70]. This is because of the complex interaction between the microbial community and 
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its host, especially in the production of metabolites that are active against a narrow spectrum 
and a broad spectrum of invasive pathogens. Nanotechnological and genetic engineering 
approaches could widen the precision and spectrum of activity of bacteriocins in future, mak-
ing them the next generation of antimicrobials [71]. If these products can be utilized, they 
can effectively guard against antimicrobial resistance (in addition to the maintenance of gut 
microbial homeostasis) and can serve as therapeutic alternatives in the treatment of inflam-
matory bowel diseases, irritable bowel syndrome, colorectal cancer, and extra-intestinal 
diseases such as diabetes. Scientists believe that probiotics will replace antibiotics as drugs 
vetted by the FDA and European regulatory bodies in the nearest future. This laudable goal 
is dependent on the correct identification of probiotic strains (with the aid of next-generation 
sequencing technologies), the palatability of these strains to the sensory organ, validated stor-
age and transport of intact cells to the gut (via microencapsulation approaches, or functional 
foods, and the fulfillment of all requirements and validation of all necessary stages for its 
approval as a new drug [72].
There is also a proposal that gut microbes can be genetically engineered so that they possess 
characteristics that detect what food is present in the gut, monitor inflammation, detect and 
fight against gastrointestinal pathogens thereby reducing reliance on antibiotics, and exert 
extra-intestinal effects such as the regulation of behavior and mood and treatment of cancer 
[73]. Genetically engineered microbes have been reported to be effective against Vibrio cholerae 
in mice especially when this pathogen was ingested 8 hours after the administration of the 
genetically engineered microbe [74]. There are still many ongoing trials seeking to manipu-
late and monitor the activities of genetically-engineered microbes in the gut, albeit in animal 
models. These microbes have to be tested for their safety and their ability to be fit enough to 
endure gastrointestinal conditions (stomach acid and bile) and successfully colonize the host’s 
gut [75]. There is also the fear about the effect of horizontal recombinant gene transfer on the 
natural gut commensals. Although microbiome engineering is challenging, it is expected that 
this strategy will be less expensive and more effective than the traditional methods of gastro-
intestinal and other extra-intestinal disease control if achieved [76]. The major goal of genetic 
manipulation of gut microbes is to improve the health of humans.
8. Conclusions
One of the most effective ways to reduce the abundance of multi-drug resistant pathogens is 
with the use of beneficial microorganisms and/or their metabolites, analogous to the  effective 
environmentally-friendly biological method of eliminating stubborn pests in farmlands by 
agriculturalists. The benefits of the gut microbiota are being constantly unraveled as advanced 
next-generation sequencing techniques arise. The field of microbio-therapeutics is steadily 
growing. Harnessing the potentials of these microbes is paramount to making the world a 
healthier and better place to live.
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